MedTrace Logo

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

NCT00433459 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2134

Last updated 2020-03-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.

Conditions

Interventions

DRUG

cyclophosphamide

drug is used in first line treatment in combination (COPP or COPDAC)

DRUG

dacarbazine

drug is used in first line treatment in combination (COPDAC)

DRUG

prednisolone

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

DRUG

prednisone

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

DRUG

procarbazine hydrochloride

drug is used in first line treatment in combination (COPP)

DRUG

vincristine sulfate

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

RADIATION

fludeoxyglucose F 18

used as a diagnostic marker for metabolically active tumour at staging and response assessment

RADIATION

radiation therapy

part of combination treatment (combined modality between chemo- and radiotherapy)

Sponsors & Collaborators

  • Deutsche Krebshilfe e.V., Bonn (Germany)

    collaborator OTHER

  • Euronet Worldwide

    collaborator OTHER

  • Christine Mauz-Körholz

    lead OTHER

Principal Investigators

  • Dieter Koerholz, MD · Martin-Luther-Universität Halle-Wittenberg

  • W. Hamish Wallace, MD · Royal Hospital for Sick Children

  • Judith Landman-Parker, MD · Hopital d'Enfants Trousseau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433459 on ClinicalTrials.gov